Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Culture

New Niemann-Pick Mouse Engineered

It is with good reason that Edward Schuchman calls Niemann-Pick Disease type A a “very, very challenging disease.” The neurodegenerative disorder is rare, kills those who have it by age 2 or 3, and has no known cure. But in May, Schuchman and his research team at Mount Sinai Medical Center in New York announced a breakthrough in their work on the disease.

There are three mutations that account for more than 90% of NPD-A cases among Ashkenazic Jews. Approximately one in 80 Ashkenazic Jews are carriers of the mutations that cause NPD-A.

The mutations that cause NPD-A affect an enzyme called acid sphingomyelinase and prevent the enzyme from performing its normal function of breaking down fats. As a result, fatty deposits accumulate in the vital organs, including the brain. Although a child who has NPD-A may appear healthy at birth, symptoms from the fat buildup typically show by six months.

The recent breakthrough came when Schuchman’s team at Mount Sinai’s International Center for Types A and B Niemann-Pick Disease successfully engineered mice with genes that express the mutant enzyme. Experiments that will attempt to enhance the activity of the malfunctioning enzyme are slated to begin in 2010. The researchers previously experimented on mice that were engineered to lack ASM, unlike human Niemann-Pick type A patients, who actually have the enzyme, albeit functioning improperly.

The new mouse, said Schuchman, “should be much more useful in research aimed at treating Niemann-Pick type A.”

There is currently no treatment for NPD-A. “We don’t yet have a therapy we think could work clinically,” Schuchman said.

Schuchman noted that an emphasis on prevention through genetic screening might have reduced the number of cases of the disease. “The Ashkenazi community is educated and aware of these diseases.” But, he added, “It doesn’t mean you stop doing research.”

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you move on, I wanted to ask you to support the Forward’s award-winning journalism during our High Holiday Monthly Donor Drive.

If you’ve turned to the Forward in the past 12 months to better understand the world around you, we hope you will support us with a gift now. Your support has a direct impact, giving us the resources we need to report from Israel and around the U.S., across college campuses, and wherever there is news of importance to American Jews.

Make a monthly or one-time gift and support Jewish journalism throughout 5785. The first six months of your monthly gift will be matched for twice the investment in independent Jewish journalism. 

—  Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.